Elyse Tung, PharmD, BCACP; Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP
This activity is jointly provided by Global Education Group and Integritas Communications.
This activity is supported by an educational grant from Gilead Sciences, Inc.
In collaboration with the American Academy of HIV Medicine (AAHIVM).
Elyse Tung, PharmD, BCACP
Clinical Assistant Professor
University of Washington School of Pharmacy
Director of Clinical Services
Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP
Department of Pharmacy Practice
Jefferson College of Pharmacy
Thomas Jefferson University
The educational design of this activity addresses the needs of clinical pharmacists who contribute to or will contribute to human immunodeficiency virus (HIV) prevention and/or management services.
Statement of Need/Program Overview
Although HIV incidence in the United States has declined over the last decade, the most recent data from the Centers for Disease Control and Prevention (CDC) identified 37,600 new HIV infections in 2014.1 Moreover, despite the overall gains, certain cohorts remain at particularly high risk of acquiring HIV, including men who have sex with men, heterosexual persons who engage in certain high-risk behaviors, and people who inject drugs.2 As part of a high-impact plan to reduce new HIV infections, the CDC has issued recommendations on the use of pre-exposure prophylaxis (PrEP)—in conjunction with other risk-reduction strategies—for certain high-risk populations.2 Many health care providers, however, are unfamiliar with the details of PrEP; this unfamiliarity is often further complicated by misinformation or personal attitudes that negatively affect the management of high-risk individuals.3,4 Pharmacists are well-positioned to help close gaps in HIV prevention via appropriate testing, counseling for at-risk individuals, and patient interactions related to PrEP initiation and ongoing monitoring.5 In this Point-of-Care 101 webinar, expert faculty will discuss recent trends in HIV incidence, CDC guidelines regarding HIV testing, and recommendations on PrEP eligibility and longitudinal prescriptions that are relevant to clinical pharmacists. The goal is to provide practicing pharmacists with the tools they need to participate and collaborate in the provision of HIV prevention and treatment services.
- CDC Fact Sheet. HIV Incidence: Estimated Annual Infections in the U.S., 2008-2014. 2017.
- US Public Health Service. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States−2014: A Clinical Practice Guideline. www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.pdf. Accessed October 5, 2017.
- CDC. HIV Surveillance Sup plemental Report 2015; 20 (No. 1). www.cdc.gov/hiv/library/reports/surveillance. Accessed October 5, 2017.
- Shaeer KM, et al. Exploratory survey of Florida pharmacists' experience, knowledge, and perception of HIV pre-exposure prophylaxis. J Am Pharm Assoc. 2014;54(6):610-617.
- Schafer JJ, et al. ASHP guidelines on pharmacist involvement in HIV care. Am J Health Syst Pharm. 2016;73(7):468-494.
Upon completion of this activity, the participant should be better able to:
- Provide universal HIV screening per CDC guidelines
- Employ CDC guidelines for identification of at-risk individuals who will benefit from use of PrEP
- Counsel clients/patients regarding PrEP efficacy, safety, and monitoring
- Support clients’/patients’ PrEP adherence and risk-behavior reduction through patient engagement and open dialogue
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Global Education Group designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
This is a knowledge-based activity.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must complete the posttest and program evaluation. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.
Microsoft Windows 2000 SE or above.
Flash Player Plugin (v126.96.36.199 or greater)
Internet Explorer (v5.5 or greater), or Firefox
Adobe Acrobat Reader*
MAC OS 10.2.8
Flash Player Plugin (v188.8.131.52 or greater)
Adobe Acrobat Reader*
Internet Explorer is not supported on the Macintosh.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this activity:
Elyse Tung, PharmD, BCACP Advisory Board: Gilead Sciences, Inc.; Speakers Bureau: Gilead Sciences, Inc.
Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Grants/Research Support: Merck & Co, Inc.
The following planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this activity:
Lindsay Borvansky Nothing to disclose
Ashley Marostica, RN, MSN Nothing to disclose
Andrea Funk Nothing to disclose
Jim Kappler, PhD Nothing to disclose
Jeanette Ruby, MD Nothing to disclose
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommend